Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

Claudia Lebedinsky, MD, Stephen P. Anthony, DO, Golam Mohi, PhD, Huyuan Yang, PhD, Jian Mei, PharmD, Edgar Braendle, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-134039

Published: 2020

Journal Articles

Anti-Pegaspargase, Anti-Calaspargase Pegol , and Anti-Polyethelene Glycol Antibody Incidence in High Risk Acute Lymphoblastic Leukemia Patients Receiving Pegaspargase or Calaspargase Pegol and Associated Anaphylactic or Hypersensitivity Reaction Rates: Results from Children's Oncology Group (COG) Study AALL07P4

Reuven J Schore, MD, Meenakshi Devidas, PhD, Archie Bleyer, MD, Gregory Reaman, MD, Claudia Lebedinsky, MD, Hui Zhang, MS, Herwig Koppensteiner, PhD, Mignon L. Loh, MD, Elizabeth Raetz, MD, Naomi Winick, MD, William L. Carroll, MD, Stephen P. Hunger, MD, Anne Angiolillo, MD

Blood (2016) 128 (22): 3965.

https://doi.org/10.1182/blood.V128.22.3965.3965

Published: 2016

Journal Articles

Systematic Literature Review Evidence of Pegaspargase for Treatment of Acute Lymphoblastic Leukemia (ALL)

Claudia Lebedinsky, MD, Michael D Hale, PhD, Jilpa Patel, MBBS, MS, Montserrat Casamayor, MD PhD, Tom Wijnands, MSc, Shrenik Desai, MS, RAC

Blood (2016) 128 (22): 5155.

https://doi.org/10.1182/blood.V128.22.5155.5155

Published: 2016

Journal Articles

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

Frank Giles, MD MB, FRCPI, FRCPath, Sarina A. Piha-Paul, MD, Alexander I. Spira, PhD MD FACP, Fadi Braiteh, MD CPI, Julio Antonio Peguero, MD, Daniel L. Spitz, MD FACP, James A. Knost, MD, Lee Schwartzberg, MD FACP, Steven Stein, MD, August J. Salvado, MD, Claudia Lebedinsky, MD, Barinder Kang, PhD, Eric Slosberg, PhD

Blood (2014) 124 (21): 4818.

https://doi.org/10.1182/blood.V124.21.4818.4818

Published: 2014

Journal Articles

Long-Term Follow Up Of a Randomized Phase II Study Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Catriona HM Jamieson, MD, PhD, Nashat Y Gabrail, MD MRCP, Claudia Lebedinsky, MD, Guozhi Gao, PhD, Moshe Talpaz, MD

Blood (2013) 122 (21): 4047.

https://doi.org/10.1182/blood.V122.21.4047.4047

Published: 2013

Journal Articles

A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF.

Moshe Talpaz, MD, Catriona Jamieson, MD, PhD, Nashat Y Gabrail, MD, Claudia Lebedinsky, MD, Guozhi Gao, PhD, Feng Liu, PhD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD

Blood (2012) 120 (21): 2837.

https://doi.org/10.1182/blood.V120.21.2837.2837

Published: 2012

NARROW

A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

Systematic Literature Review Evidence of Pegaspargase for Treatment of Acute Lymphoblastic Leukemia (ALL)

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

Long-Term Follow Up Of a Randomized Phase II Study Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF.

Email alerts

ASH Publications

American Society of Hematology

A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

Systematic Literature Review Evidence of Pegaspargase for Treatment of Acute Lymphoblastic Leukemia (ALL)

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

Long-Term Follow Up Of a Randomized Phase II Study Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)

A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only